Advertisement
Screener

ABEONA THERAPEUTICS INC. (ABEO) Graph

ABEO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $11.38M; Revenue including tax (m); Cost of revenue $4.18M; Research and development $5.02M.
  • 2026-03-31: Revenue $8.72M; Revenue including tax (m); Cost of revenue $2.70M; Research and development $9.55M.
  • 2025-12-31: Revenue $5.42M*; Revenue including tax (m); Cost of revenue $1.04M*; Research and development $6.71M*.
  • 2025-09-30: Revenue (m); Revenue including tax (m); Cost of revenue $488.00K; Research and development $4.22M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ABEO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$11.38MRevenue$11.38MCost of revenue$4.18MOperating income-$13.65MResearch & development$5.02MSelling, general& administrative$15.84MPre-tax income-$20.19MNet income-$20.19M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ABEO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Single ReportableSegment$11.38MRevenue$11.38MCost of revenue$4.18MOperating income-$13.65MResearch & development$5.02MSelling, general& administrative$15.84MPre-tax income-$20.19MNet income-$20.19M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$11.38M(m)$4.18M$5.02M$15.84M(m)(m)-$20.19M
2026-03-31$8.72M(m)$2.70M$9.55M$19.50M(m)$2.00K-$17.07M
2025-12-31$5.42M*(m)$1.04M*$6.71M*$18.78M*(m)-$215.00K*-$162.83M*
2025-09-30(m)(m)$488.00K$4.22M$19.31M(m)-$15.20M-$5.16M
2025-06-30$400.00K(m)(m)$5.94M$17.15M$23.19M$15.51M$108.83M
2025-03-31(m)(m)(m)$9.94M$9.79M$19.73M(m)-$12.03M
2024-12-31(m)(m)(m)(m)(m)$16.67M*(m)(m)
2024-09-30(m)(m)(m)$8.94M$6.40M$15.35M(m)-$30.27M
2024-06-30(m)(m)(m)$9.22M$8.65M$17.86M(m)$7.41M
2024-03-31(m)(m)(m)$7.21M(m)$14.33M(m)-$31.58M
2023-09-30(m)(m)(m)$7.15M(m)$11.33M(m)-$11.84M
2023-06-30$3.50M(m)(m)$8.52M(m)$14.05M(m)-$16.65M
2023-03-31(m)(m)(m)$8.04M(m)$12.04M(m)-$9.11M
2022-09-30(m)(m)(m)$5.49M(m)$9.38M(m)-$6.43M
2022-06-30$1.00M(m)(m)$6.66M(m)$9.01M(m)-$4.10M
2022-03-31$346.00K(m)(m)$10.54M(m)$20.94M(m)-$22.04M
2021-09-30(m)(m)(m)$9.06M(m)$14.87M(m)-$7.04M
2021-06-30(m)(m)(m)$8.53M(m)$13.71M(m)-$15.21M
2021-03-31(m)(m)(m)$8.32M(m)$14.60M(m)-$16.00M
2020-09-30$7.00M(m)(m)$7.97M(m)$13.25M(m)-$7.24M
2020-06-30(m)(m)(m)$6.11M(m)$12.48M(m)-$13.01M
2020-03-31(m)(m)(m)$6.82M(m)$48.21M(m)-$48.16M
2019-12-31(m)(m)(m)$9.61M(m)(m)(m)-$16.43M
2019-09-30(m)(m)(m)$10.92M(m)$17.65M(m)-$17.37M
2019-06-30$0.00(m)(m)$16.31M(m)$23.98M(m)-$23.92M
2019-03-31$0.00(m)(m)$11.74M(m)$19.05M(m)-$18.55M
2018-12-31(m)(m)(m)$9.47M(m)(m)(m)-$17.48M
2018-09-30$1.71M(m)(m)$13.15M(m)$18.63M(m)-$16.42M
2018-06-30$276.00K$819.00K(m)$7.92M(m)(m)(m)-$12.24M
2018-03-31$531.00K(m)(m)$8.16M(m)(m)(m)-$10.53M
2017-12-31(m)(m)(m)$5.71M(m)(m)(m)-$8.45M
2017-09-30$219.00K(m)(m)$3.28M(m)(m)(m)-$5.34M
2017-06-30$217.00K$217.00K(m)$5.81M(m)(m)(m)-$8.28M
2017-03-31$186.00K(m)(m)$2.20M(m)(m)(m)-$5.25M
2016-09-30$184.00K(m)(m)$2.75M(m)(m)(m)-$2.62M
2016-06-30$214.00K(m)(m)$3.02M(m)(m)(m)-$6.70M
2016-03-31$235.00K(m)(m)$1.85M(m)(m)(m)-$5.54M
2015-09-30$285.00K(m)(m)$1.58M(m)(m)(m)-$6.07M
2015-06-30$282.00K(m)(m)$610.00K(m)(m)(m)-$4.11M
2015-03-31$258.00K(m)(m)$453.00K(m)(m)(m)-$2.00M
2014-12-31(m)(m)(m)(m)$657.00K*(m)(m)(m)
2014-09-30$236.00K(m)(m)$73.00K$795.00K(m)(m)-$1.47M
2014-06-30$247.00K(m)(m)$81.00K$868.00K(m)(m)-$12.51M
2014-03-31$208.00K(m)(m)$144.00K$733.00K(m)(m)-$859.00K
2013-09-30$189.00K(m)(m)$236.00K$642.00K(m)(m)-$157.00K
2013-06-30$467.00K(m)(m)$197.00K$2.14M(m)(m)$1.60M
2013-03-31$1.22M(m)(m)$323.00K$1.34M(m)(m)$4.08M
2012-09-30$871.00K(m)(m)$308.00K$1.42M(m)(m)-$14.87M
2012-06-30$690.00K(m)(m)$654.00K$1.41M(m)(m)-$10.60M
2012-03-31$1.84M(m)(m)$750.00K$1.66M(m)(m)-$4.89M
2011-09-30$1.04M(m)(m)$906.00K(m)(m)(m)$350.00K
2011-06-30$150.00K(m)(m)$903.00K(m)(m)(m)-$1.26M
2011-03-31$150.00K(m)(m)$1.12M(m)(m)(m)-$1.90M
2010-09-30$127.00K(m)(m)$1.20M(m)(m)(m)-$12.72M
2010-06-30$105.00K(m)(m)$733.00K(m)(m)(m)$1.79M

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$20.10M(m)$6.87M$14.58M$35.34M(m)$2.00K-$37.27M
2025-06-30$400.00K(m)(m)$15.88M$26.93M$42.92M$15.51M$96.80M
2024-06-30(m)(m)(m)$16.43M$15.77M$32.19M(m)-$24.17M
2023-06-30$3.50M(m)(m)$16.56M(m)$26.09M(m)-$25.76M
2022-06-30$1.35M(m)(m)$17.20M(m)$29.95M(m)-$26.14M
2021-06-30(m)(m)(m)$16.87M(m)$28.31M(m)-$31.21M
2020-06-30(m)(m)(m)$12.93M(m)$60.69M(m)-$61.17M
2019-06-30$0.00(m)(m)$28.04M(m)$43.03M(m)-$42.48M
2018-06-30$807.00K$3.42M(m)$16.08M(m)(m)(m)-$22.77M
2017-06-30$403.00K$403.00K(m)$8.01M(m)(m)(m)-$13.53M
2016-06-30$449.00K(m)(m)$4.87M(m)(m)(m)-$12.25M
2015-06-30$540.00K(m)(m)$1.06M(m)(m)(m)-$6.11M
2014-06-30$455.00K(m)(m)$225.00K$2.26M(m)(m)-$13.37M
2013-06-30$1.69M(m)(m)$520.00K$3.48M(m)(m)$5.68M
2012-06-30$2.53M(m)(m)$1.40M$3.07M(m)(m)-$15.49M
2011-06-30$300.00K(m)(m)$1.92M(m)(m)(m)-$3.16M
2010-06-30$207.00K(m)(m)$1.52M(m)(m)(m)$2.88M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$400.00K$488.00K$20.10M$46.25M(m)$315.00K$91.64M
2024-09-30(m)(m)$25.37M$22.17M$47.54M(m)-$54.44M
2023-09-30$3.50M(m)$23.71M(m)$37.43M(m)-$37.60M
2022-09-30$1.35M(m)$22.69M(m)$39.33M(m)-$32.58M
2021-09-30(m)(m)$25.92M(m)$43.18M(m)-$38.25M
2020-09-30$7.00M(m)$20.90M(m)$73.94M(m)-$68.41M
2019-09-30(m)(m)$38.96M(m)$60.68M(m)-$59.85M
2018-09-30$2.52M(m)$29.23M(m)$42.67M(m)-$39.19M
2017-09-30$622.00K(m)$11.28M(m)(m)(m)-$18.87M
2016-09-30$633.00K(m)$7.62M(m)(m)(m)-$14.87M
2015-09-30$825.00K(m)$2.64M(m)(m)(m)-$12.19M
2014-09-30$691.00K(m)$298.00K$3.06M(m)(m)-$14.84M
2013-09-30$1.88M(m)$756.00K$4.12M(m)(m)$5.52M
2012-09-30$3.40M(m)$1.71M$4.49M(m)(m)-$30.36M
2011-09-30$1.34M(m)$2.82M(m)(m)(m)-$2.81M
2010-09-30$334.00K(m)$2.72M(m)(m)(m)-$9.84M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$5.82M$1.53M$26.81M$65.03M(m)$100.00K-$71.18M
2024-12-31(m)(m)$34.36M$29.85M$64.21M(m)$63.73M
2023-12-31$3.50M(m)$31.09M(m)$50.63M(m)$54.19M
2022-12-31$1.41M(m)$28.96M(m)$52.33M(m)-$39.70M
2021-12-31$3.00M(m)$38.73M(m)$92.84M(m)-$84.94M
2020-12-31$10.00M(m)$30.14M(m)$91.42M(m)-$84.23M
2019-12-31(m)(m)$48.57M(m)$77.09M(m)-$76.28M
2018-12-31$3.00M(m)$38.70M(m)$61.16M$0.00-$56.67M
2017-12-31$837.00K(m)$16.99M(m)$28.67M$0.00-$27.32M
2016-12-31$889.00K(m)$10.65M(m)(m)$0.00-$21.87M
2015-12-31$1.04M(m)$4.71M(m)(m)$0.00-$14.53M
2014-12-31$925.00K(m)$333.00K$3.71M(m)$0.00-$26.78M
2013-12-31$2.04M(m)$884.00K$4.83M(m)$0.00$4.45M
2012-12-31$4.40M(m)$2.01M$6.02M(m)$0.00-$10.53M
2011-12-31$1.84M(m)$3.58M$5.75M(m)$17.00K-$2.53M
2010-12-31$481.00K(m)$3.35M(m)(m)$0.00-$7.54M

Similar stocks

Stock NameCountryMarket CapPE Ratio
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Evommune, Inc. (EVMN)United States$0.320B-5.10
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40